Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs.
 
Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which  Altheos licensed from a Japanese pharmaceutical company.  The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital.